Corporate

BOARD AND MANAGEMENT

Board of Directors
  • John J. Swift
    John J. Swift Chair, Board of Directors
    John Swift is a lawyer in Vancouver, British Columbia, with an independent practice centered on organizing, financing and advising knowledge-based businesses, and on technology transfer from public institutions and universities. John Swift is currently a member of the Board of Trustees of the Vancouver Public Library.
    John Swift has served on the Boards of Inex Pharmaceuticals, Ultrasonix Medical Corporation and NeuroMed Technologies Inc., the National Arts Centre, Arts Umbrella and has recently retired as the Chairman of the Central City Foundation. In 1984 John Swift was Principal Secretary to the Prime Minister and, subsequently, Chief of Staff, Office of the Leader of the Opposition, Government of Canada.
    • Jason Flowerday
      Jason Flowerday CEO and Director
      Mr. Flowerday has extensive life sciences leadership experience including over a decade of business development and marketing work for two of the world’s largest pharmaceutical companies, Germany’s Bayer AG and US-based Johnson and Johnson. Other notable positions include executive leadership and entrepreneurial roles with Knight Therapeutics and Pro Bono Bio Inc. Mr. Flowerday was also co-founder and co-owner of both Orphan Canada and RxMedia Healthcare Communications. He is an independent Director of Aequus Pharmaceuticals.
      • Dr. Sabine Mai, PhD
        Dr. Sabine Mai, PhD Director and Chair, Clinical and Scientific Advisory Board
        Dr. Sabine Mai is currently Professor of Physiology and Pathophysiology, Biochemistry and Medical Genetics, Human Anatomy and Cell Science, University of Manitoba. She is also Director of The Genomic Centre for Cancer Research and Diagnosis (GCCRD) at University of Manitoba.
        She is an internationally known researcher who has more than one hundred publications related to research on Genomics and Genomic Instability. Most recently she has contributed to a library of patents related to her work on 3D Genomic Analysis. She is the recipient of several academic awards including the Braidwood Jackson Memorial Award; the Dr. Saul Highman Memorial Award; the Rh Award (Basic Science); the J&J Cognition Challenge (2013). She was recognized in 2015 as one of the Top 100: Canada’s Most Powerful Women.
        Dr. Mai has dedicated her life to the research of Cancer and other debilitating diseases. She has been instrumental in the development of innovative 3D analysis of genomic instability, which will help in diagnosing more specifically and earlier several forms of Cancer. This will allow physicians to personalize treatment and improve the quality of outcomes. During the course of more than twenty years of research she has contributed to a portfolio of patents protecting her discoveries. Her vision is to use her discoveries for the benefit of patients everywhere.
        • Gordon McCauley
          Gordon McCauley Director
          Gordon McCauley has more than 20 years’ experience in healthcare businesses. He is President and CEO of Viable Healthworks Corp. a national healthcare service firm, and remains a Partner in NDI Capital, a healthcare investment business he co-founded in 2000. Mr. McCauley served as President and CEO of Allon Therapeutics, a publicly traded biotechnology company in the NDI portfolio, from 2004 to July of 2013.
          Prior to co-founding NDI, he led the successful growth and development of two Canadian healthcare companies. Outside of the healthcare industry, Mr. McCauley has been a senior sales and public affairs executive for a Canadian multinational energy company and served in a staff capacity to two Prime Ministers and former Ontario Premier David Peterson.
          • Bruce Colwill
            Bruce Colwill Director
            Bruce Colwill is a strategic finance professional with over 25 years of experience in start-up and entrepreneurial companies. As the CFO of multiple public and private companies, Bruce has been responsible for fundraising in excess of US$400 million including private and public financing, debt and other structured financings.
            Beginning his career with KPMG, Bruce’s expertise encompasses the biotech and pharmaceutical industry, the mining and energy sectors and financial services. He brings experience in IPOs, managing growth, mergers & acquisitions and general corporate management to the Board. He holds a BBA from Simon Fraser University and is a Canadian Professional Accountant (CPA,CA).
            • Ferenc Somogyvari
              Ferenc Somogyvari Director
              Ferenc Somogyvari has worked for over 38 years in the optical medical and biology industries after working with Touche Ross as an auditor. He has worked in various positions over the years from Territory sales, technical specialist, sales manager and finally over the last decade as General Manager for Carl Zeiss Microscopy in Canada. He is the former CEO of 3D Signatures Inc.
              He led the transition of Carl Zeiss Canada from informal to formal business practices to take advantage of synergies within their global corporate framework. He is known as an effective team builder particularly where diverse personalities work together as professionals. He brings with him a complete set of corporate skills in managing a technology-based company.
              • Helen Stevenson
                Helen Stevenson Director
                Helen Stevenson is Founder and Chief Executive Officer of Reformulary Group Inc., a company dedicated to helping manage prescription drug costs for employer drug plans while promoting better patient health outcomes. Ms. Stevenson was formerly Executive Officer of Canada’s largest provincial drug program, the Ontario Public Drug Program by Order-In-Council, as well as Assistant Deputy Minister at the Ontario Ministry of Health and Long-Term Care. Ms. Stevenson led two major transformations in the prescription drug system; first with Ontario’s Bill 102 (2006) and, more recently, with the Province’s generic pricing reforms (2010). In addition, she led many of Ontario’s drug system initiatives, including the Drugs for Rare Diseases Framework, Ontario Narcotics Strategy, Ontario Citizens’ Council, MedsCheck medication review program, Compassionate Access Program, Competitive Agreements Framework, and the Drug Innovation Fund. Ms. Stevenson is a member of the Board of Trustees of the Auto Sector Retiree Health Care Trust, and a former member of the Board of North York General Hospital.
                Management
                • Jason Flowerday
                  Jason Flowerday CEO and Director
                  Mr. Flowerday has extensive life sciences leadership experience including over a decade of business development and marketing work for two of the world’s largest pharmaceutical companies, Germany’s Bayer AG and US-based Johnson and Johnson. Other notable positions include executive leadership and entrepreneurial roles with Knight Therapeutics and Pro Bono Bio Inc. Mr. Flowerday was also co-founder and co-owner of both Orphan Canada and RxMedia Healthcare Communications. He is an independent Director of Aequus Pharmaceuticals.
                  • Joost van der Mark
                    Joost van der Mark Chief Business Officer
                    Mr. van der Mark is a seasoned healthcare executive with over two decades of experience in the biopharmaceutical industry and joined 3D Signatures as Chief Business Officer responsible for business development. Prior to joining 3D Signatures, Mr van der Mark served as the Vice President of Corporate Development of BioSyent Inc. responsible for the acquisition and licensing activities for the corporation. Mr van der Mark was co-founder and co-owner of Orphan Canada Inc. prior to it’s sale to Knight Therapeutics and prior to this had progressive positions at Nycomed (Takeda), Sanofi Pasteur and Bayer Mr. van der Mark holds an M.Sc. in Physiology and Pharmacology from the University of Western Ontario and an M.B.A. from Schulich School of Business.
                    • Keith B. Cassidy
                      Keith B. Cassidy Chief Financial Officer
                      Keith Cassidy is an accountant with significant experience in professional services management (legal), as well as health care and education, at strategic and leadership levels. Keith Cassidy has served as VP Finance and CFO for the Royal Victoria Hospital.
                      He has held Executive Director positions with several major law firms including Davies Ward Phillips & Vineberg LLP; McMillan LLP; and Bennett Jones LLP. He has also lectured in Business Administration at John Abbott College in Montreal.
                      • Oumar Samassekou
                        Oumar Samassekou VP Clinical Technology
                        Oumar Samassekou, PhD, is trained in medical genetics, cytogenetics and other molecular genetics.  During his Ph.D. and post-doctoral trainings, Dr. Samassekou developed expertise on prenatal diagnosis and cancer genomics.  He has worked on the development of a non-invasive diagnostic procedure to detect fetal chromosomal abnormalities from maternal peripheral blood.
                        In regards to his background in cancer genomics research, Dr. Samassekou has studied the length of individual telomeres, telemetric nuclear architecture, and genomic instability in leukemia and breast cancer. In addition to his competencies in research, he has been trained in a clinical laboratory examining both molecular genetics and cytogenetics. Dr. Samassekou was the supervisor of a molecular pathology unit in one of the largest laboratories specializing in clinical pathology of breast cancer in Canada. Dr. Samassekou has also developed competency to supervise analytical and clinical validation of different clinical diagnostic, prognostic and predictive tests.
                        • Hugh Rogers
                          Hugh Rogers VP Finance
                          Mr. Rogers is an entrepreneur and lawyer with broad private and public company experience in business management, regulatory compliance, finance and investor relations. Recent work includes corporate finance advisory positions in a range of industries from health sciences and agribusiness to mining and oil and gas.
                          Recent experience also includes corporate restructuring under the Companies’ Creditors Arrangement Act and disposition of distressed assets. Mr. Rogers holds a B.Sc. and LLB. He is a member in good standing of the Law Society of British Columbia.
                          Scientific Advisory

                          Kenneth C. Anderson, MD

                          Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics Institute Physician
                          Kraft Family Professor of Medicine, Harvard Medical School

                          Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School, as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at Johns Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in it is microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.

                          Laurence Klotz, MD

                          Professor, Department of Surgery, University of Toronto, past Chief of Urology, Sunnybrook Health Sciences Centre, Toronto, and Chairman, World Uro-Oncology Federation

                          Dr. Klotz is internationally recognized for his contributions to the treatment of prostate cancer, notably for pioneering the adoption of Active Surveillance as a standard aspect of patient care. Dr. Klotz obtained his medical degree and residency training from the University of Toronto with a special fellowship in uro-oncology and tumour biology at Memorial Sloan Kettering Cancer Centre, New York. He is a widely published uro-oncologist who serves on the board or heads many medical/scientific organizations. He is a Professor, Department of Surgery, University of Toronto, past Chief of Urology, Sunnybrook Health Sciences Centre, Toronto, and Chairman, World Uro-Oncology Federation. Dr. Klotz was awarded the Order of Canada in 2014 for his contribution to prostate cancer treatment.

                          Hans Knecht, MD

                          Professor of Medicine and Chief, Division of Haematology at McGill University and Jewish General Hospital, Montreal

                          Dr. Knecht established himself as a prominent haematologist through his ground-breaking translational research on lymphoma biology. His current focus is on the molecular events leading to the transition from the mononuclear Hodgkin to the multinuclear Reed-Sternberg cell and the impact of 3D nuclear telomere organization on this transformation. Dr. Knecht received his medical degree from the University of Zurich, Switzerland with post-graduate work under both Maxime Seligmann (Haematology) and Karl Lennert (Haematopathology) in Paris and Kiel, respectively. Dr. Knecht is currently a Professor of Medicine and Chief, Division of Haematology at McGill University and Jewish General Hospital, Montreal.

                          Darrel Drachenberg, MD

                          Urologic Oncologist
                          Assistant Professor
                          Director of Research, Manitoba Prostate Center
                          Section of Urology, Department of Surgery,  University of Manitoba
                          Chair, Genito-Urinary Oncology Disease Site Group,
                          CancerCare Manitoba

                          Dr. Drachenberg is a urologic oncologist and researcher and strong proponent of Active Surveillance for prostate cancer patients. Dr. Drachenberg attended medical school at the University of British Columbia and urology residency at Dalhousie University. He is an American Foundation of Urology Scholar with fellowship training in urologic oncology at the National Cancer Institute in Bethesda, Maryland. He founded the laparoscopic urology program and prostate brachytherapy, cryotherapy, and HIFU programs at the University of Manitoba where he works as assistant professor of surgery and director of research for the Manitoba Prostate Center and Section of Urology and Chair of the Genito-Urinary disease site group, CancerCare Manitoba.

                          Rami Kotb, MD

                          Department of Medical Oncology & Hematology, CancerCare Manitoba

                          Dr. Kotb completed his medical residency training in Paris, France, and then became a staff member at Paris XI University. He joined the Hematology-Oncology team at Sherbrooke University (QC, Canada) in 2005 as an Assistant, then Associate Professor. He also worked as the Director of Hematology undergraduate education, Head of the supra-regional team of Hematological Neoplasia and Head of the Institutional Oncology Quality Sub-committee. Late 2011, he moved to British Columbia to work at the BC Cancer Agency as an Oncologist/Hematologist, Associate Professor at the University of British Columbia and affiliate Professor at the University of Victoria. He joined the team at CancerCare Manitoba in September 2014. His practice and research activity will be focused on lymphoid neoplasia, primarily myeloma and lymphoma.

                          Thomas Cremer, MD

                          Professor emeritus of Anthropology and Human Genetics, Ludwig Maximilians University (LMU), Munich, Germany

                          Dr. Cremer is an internationally-recognized scientist specializing in the studies of nuclear architecture. He is one of the pioneers of interphase cytogenetics and comparative genomic hybridization (CGH). These methods have become widely used tools for cytogenetic analyses of chromosomal imbalances.

                          He is a corresponding member of the Heidelberg Academy for Sciences and Humanities since 2000, a member of Germany’s National Academy of Sciences Leopoldina since 2006, a honorary member of both the European Cytogenetics Association (ECA) and the German Society of Human Genetics since 2011, as well as the recipient of the medal of Honor of this Society.

                          Ian Smith, PhD, OC

                          Chairman of the Board at Centre for Imaging Technology Commercialization, CIMTEC

                          Dr. Smith, OC, PhD, DSc, FRSC, is currently the Chairman of the Centre for Imaging Technology Commercialization. His past research and commercialization achievements include significant success in the field of magnetic resonance imaging. Dr. Smith is a former Director General of the NRC Institute for Biological Sciences, Ottawa, ON, and founder and Director General of the Institute for Biodiagnostics, Winnipeg, MB. He is a passionate advocate for the advancement of diagnostics for the early detection and treatment of disease.

                          He was appointed Officer of the Order of Canada in 2008 for his leadership in the advancement, development and commercialization of Canada’s diagnostic technologies, notably magnetic resonance imaging, in the field of health care. In addition, Dr. Smith received the 2008 Outstanding Achievement Award of the Public Service of Canada, presented to individuals who have displayed long-term excellence throughout their careers in Canada’s public service. He was awarded the Queen’s Gold (2002) and Diamond (2012) Jubilee Medals for his contributions.

                          Business Advisory

                          Jonathan Goodman

                          Director & CEO, Knight Therapeutics Inc.

                          Prior to Knight, Mr. Goodman was the co-founder, President and CEO of Paladin Labs Inc. which was acquired by Endo for $3.2 billion. Under his leadership, $1.50 invested in Paladin at its founding was worth $142 nineteen years later. Prior to co-founding Paladin in 1995, Mr. Goodman was a consultant with Bain & Company and also worked in brand management for Procter & Gamble. Mr. Goodman holds a B.A. with Great Distinction from McGill University and the London School of Economics with 1st Class Honours. Additionally, Mr. Goodman holds an LL.B. and an M.B.A. from McGill University.

                          Dr. Heiner Dreismann

                          Past President and CEO,
                          Roche Molecular Diagnostics

                          Dr. Dreismann is a seasoned executive with more than 24 years experience in the healthcare industry, and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique, one of the most ubiquitous technologies in molecular biology and genetics research today. He had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO, Roche Molecular Systems, Head of Global Business Development, Roche Diagnostics and Member of Roche’s Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Munster) in Germany.

                          John Lindsay

                          Founder, SciPartners

                          Mr. Lindsay began his career at Millipore Corporation, Merck KGaA, and quickly advanced to become the youngest Vice President in the history of the company.  He was promoted to Executive Vice President of several divisions, including the Analytical Group and Milligen Biosearch Divisions. In 2000, he founded SciPartners, with the objective of building a platform for development of early stage European and North American firms. His focus is the Life Science market, and over the past 14 years he has successfully built up sales and marketing that led to rapid growth and increased revenues for many companies, and the acquisition of ProXeon by ThermoFisher and the acquisition of Halo Genomics by Agilent.

                          Nigel Terrett

                          Former Chief Strategic Officer, LifeLabs Inc.

                          Nigel Terrett has held executive leadership roles at Excelleris Technologies, LifeLabs, MDS Inc. and MDS Diagnostics. His significant accomplishments in the life sciences sector include his tenure as Chairman of the Board of Excelleris Technologies, a medical information technology company, where he led the creation of the largest integrated patient and physician diagnostic database in Canada. As Chief Strategic Officer of LifeLabs Inc., Mr. Terrett created innovative collaborative programs with health institutions, provincial governments and health providers to improve health care while reducing costs. As Senior Vice President and General Manager of Life Labs British Columbia, Mr. Terrett was responsible for 900 operational staff, 90 branch locations and two state-of-the-art medical laboratories providing over 15 million medical results per year. In this role, he dramatically improved operational performance through Lean-Sigma methodologies. As Chief Information Officer of MDS Diagnostics Inc., he led the restructuring of information technology services that resulted in multi-million dollar savings for the company. As Vice-President of Information Technology at MDS Diagnostics, Mr. Terrett led a North American team that increased operating income by over 50%. More recently, Mr. Terrett has provided strategic advisory services to the biotech industry.

                          Mr. Terrett is experienced in every step of the diagnostics testing process, from sample collection to reporting, to providing efficient, reliable and high-quality services to enhance patient care. A respected industry leader, Mr. Terrett’s operational background and network will help facilitate the successful launch of 3DS’ new class of minimally invasive biomarker tests at a national level.

                          Harry Glorikian

                          Mr. Glorikian has over 30 years of private and public company success in the biomedical and life sciences industries and is a recognized global innovator in the field of medical diagnostics. Recent experience includes roles as Entrepreneur in Residence to GE Ventures – New Business Creation Group and as a member of the board of directors of GeneNews Ltd. He also serves on the advisory board of Nucelis and Evidation Health. Mr. Glorikian is also a co-founder and an advisory board member of DrawBridge Health. Previously he co-founded and held the position of managing director and head of consulting services for Scientia Advisors which was acquired by Precision for Medicine in 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories.